Delcath has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors.
In addition, Delcath received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. Delcath has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute.
Delcath has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute. In addition, Delcath received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors.
Delcath has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute. In addition, Delcath received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors.